Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Asthma treatment medicine

A technology for asthma and medicine, applied in the field of medicine preparation, can solve problems such as insufficient effect, delayed effect, decreased pituitary function, etc., and achieve a remarkable effect of treatment

Inactive Publication Date: 2017-04-26
郑州莉迪亚医药科技有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Western medicine mainly uses chemicals such as bronchodilators and hormones to temporarily relieve the symptoms of the attack period. However, after stopping the medicine, it often relapses when encountering external stimulation, and long-term medication may lead to a series of toxic side effects such as decreased pituitary function.
By regulating the whole body (mainly the immune system), traditional Chinese medicine increases the immunity of the body, improves the ability of the body to resist disease invasion, reduces the onset of asthma and even achieves the purpose of long-term remission; the existing traditional Chinese medicine for the treatment of asthma, the treatment time long, the effect is not obvious enough, and the effect is relatively slow, which brings a lot of pain to patients; moreover, most traditional Chinese medicines are decoctions, which need to be decocted before taking, and the decoction takes a long time, which is inconvenient to carry; Circulation, irritating to the stomach, further affecting the patient's health

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] A medicine for treating asthma, the main raw materials in parts by weight are: 5 parts of brevifolia hematoxylic acid, 30 parts of punicalagin, 12 parts of artemisinin, 3 parts of procaterol, 17 parts of aminophylline, ferulic acid 5 parts, 14 parts of dextran, 4 parts of berberine hydrochloride, 2 parts of 3-n-butenylphthalide.

[0017] A preparation method of a medicine for treating asthma, the specific steps are:

[0018] First, in a pharmaceutical-grade clean area, weigh brevifolia acid, punicalagin, artemisinin, procaterol, aminophylline, ferulic acid, dextran, berberine hydrochloride, 3-n- Butenylphthalide, sieved, mechanically mixed, added ultrapure water, placed in a pharmaceutical mixer, mixed for 4 minutes, controlled RSD ≤ 5%, mixed, pressed into tablets and dried at low temperature, controlled at 4°C, packaged. Drugs to treat asthma.

Embodiment 2

[0020] A medicine for treating asthma, the main raw materials in parts by weight are: 5 parts of brevifolia hematoxylic acid, 32 parts of punicalagin, 18 parts of artemisinin, 3 parts of procaterol, 19 parts of aminophylline, ferulic acid 9 parts, 16 parts of dextran, 5 parts of berberine hydrochloride, 2 parts of 3-n-butenylphthalide.

[0021] A preparation method of a medicine for treating asthma, the specific steps are:

[0022] First, in a pharmaceutical-grade clean area, weigh brevifolia acid, punicalagin, artemisinin, procaterol, aminophylline, ferulic acid, dextran, berberine hydrochloride, 3-n- Butenylphthalide, sieved, mechanically mixed, added ultrapure water, placed in a pharmaceutical mixer, mixed for 4 minutes, controlled RSD ≤ 5%, mixed, pressed into tablets and dried at low temperature, controlled at 4°C, packaged. Drugs to treat asthma.

Embodiment 3

[0024] A medicine for treating asthma, the main raw materials in parts by weight are: 6 parts of brevifolia hematoxylic acid, 35 parts of punicalagin, 21 parts of artemisinin, 4 parts of procaterol, 21 parts of aminophylline, ferulic acid 11 parts, 17 parts of dextran, 7 parts of berberine hydrochloride, 5 parts of 3-n-butenylphthalide.

[0025] A preparation method of a medicine for treating asthma, the specific steps are:

[0026] First, in a pharmaceutical-grade clean area, weigh brevifolia acid, punicalagin, artemisinin, procaterol, aminophylline, ferulic acid, dextran, berberine hydrochloride, 3-n- Butenylphthalide, sieved, mechanically mixed, added ultrapure water, placed in a pharmaceutical mixer, mixed for 6 minutes, controlled RSD ≤ 5%, mixed, pressed into tablets and dried at low temperature, controlled at 6°C, packaged Drugs to treat asthma.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an asthma treatment medicine. The asthma treatment medicine comprises, by weight, 5-7 parts of brervifolincaboxylic acid, 30-38 parts of punicalagin, 12-27 parts of artemisinin, 3-5 parts of procaterol, 17-23 parts of aminophylline, 5-18 parts of ferulic acid, 14-20 parts of dextran, 4-9 parts of berberine hydrochloride and 2-8 parts of 3-n-butylidenephthalide. Raw material components are strictly chosen according to the understanding mechanism of the asthma disease in order to reach the comprehensive rehabilitation purpose, and the medicine has a substantial treatment effect, and realizes treatment of both manifestation and root cause of disease.

Description

technical field [0001] The invention relates to the field of medicine preparation, in particular to a medicine for treating asthma. Background technique [0002] Asthma, also known as allergic bronchial asthma, is a worldwide frequently-occurring disease, listed by the World Health Organization as one of the four major chronic diseases, and has a very high mortality rate (the death rate occupies the fourth place among all diseases, and Taiwan's famous singer Teresa Teng died of an asthma attack). In recent years, the proportion of children among asthmatic patients has shown an upward trend (the incidence rate is 50%), which has aroused great concern from insiders. Studies have shown that asthma is generally a chronic airway inflammation caused by the participation of eosinophils, mast cells, T cells and other cells and cell components. This inflammation leads to airway hyperresponsiveness and narrowing of the airways, which manifests as recurrent attacks, wheezing, dyspnea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/721A61K31/7048A61K31/352A61K31/366A61K31/4704A61K31/522A61K31/192A61K31/4375A61K31/365A61P11/06
CPCA61K31/721A61K31/192A61K31/352A61K31/365A61K31/366A61K31/4375A61K31/4704A61K31/522A61K31/7048A61K2300/00
Inventor 不公告发明人
Owner 郑州莉迪亚医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products